Drug intelligence / Profile preview

Benzo[B]Thiophene-2-Boronic Acid

Development stage: Preclinical
Modality: Small Molecules

Overview

Benzo[B]Thiophene-2-Boronic Acid is a non-beta-lactam-based small molecule inhibitor of beta-lactamase enzymes, specifically targeting class C beta-lactamases such as AmpC from *Escherichia coli*. It has demonstrated high affinity for *E. coli* AmpC and the ability to potentiate the activity of beta-lactam antibiotics, like amoxicillin and ceftazidime, against bacteria expressing class C beta-lactamases. This compound is being investigated as a potential therapeutic agent for treating beta-lactam-resistant bacterial infections.

Targets

AmpC (AmpC beta-lactamase)

Beyond the preview

Go deeper on Benzo[B]Thiophene-2-Boronic Acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Benzo[B]Thiophene-2-Boronic Acid.

Explore the full profile